Table 5.
Analysis of MGMT methylation and TP53 expression status versus recurrence rate in glioblastoma patients receiving different chemotherapies
| Recurrence interval | P-value | Adjusted P-value | ||||
|---|---|---|---|---|---|---|
| Before 1 year | After 1 year | |||||
| n | (%) | n | (%) | |||
| MGMT status | ||||||
| Non-methylated | ||||||
| Temozolomide | 8 | (61.5) | 5 | (38.5) | 0.007b | 0.041c |
| Temozolomide + other | 0 | (0.0) | 8 | (100.0) | ||
| Methylated | ||||||
| Temozolomide | 6 | (37.5) | 10 | (62.5) | 0.667b | |
| Temozolomide + other | 2 | (25.0) | 6 | (75.0) | ||
| TP53 expression | ||||||
| Negative | ||||||
| Temozolomide | 7 | (63.6) | 4 | (36.4) | 0.040a | 0.035c |
| Temozolomide + other | 1 | (14.3) | 6 | (85.7) | ||
| Positive | ||||||
| Temozolomide | 7 | (38.9) | 11 | (61.1) | 0.201b | |
| Temozolomide + other | 1 | (11.1) | 8 | (88.9) | ||
All patients with non-methylated MGMT who received temozolomide plus other chemotherapies had delayed recurrence, after at least 1 year (P-value = 0.007) compared with patients who received TZM alone. Around 86% of patients with non-TP53 expressing tumors who received TZM plus other chemotherapies had recurrence after 1 year (P-value = 0.040)
TMZ Temozolomide
aChi-Square Test; bFisher’s Exact Test; cMantel–Haenszel Chi-square test